Actively Recruiting
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
Led by Thomas Jefferson University · Updated on 2025-07-17
400
Participants Needed
1
Research Sites
235 weeks
Total Duration
On this page
Sponsors
T
Thomas Jefferson University
Lead Sponsor
E
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to determine how to optimally utilize this low cost medication to improve maternal/child health outcomes. This is a Phase I/II randomized controlled trial of high risk pregnancies recommended aspirin; participants will be randomized to take aspirin either 162mg once daily, or 81mg twice a day. Outcomes evaluated will include the difference in aspirin response between these two dosing regimens, the individual factors that impact aspirin pharmacology in pregnancy, and evaluate markers or aspirin response that may be associated with pregnancy outcome.
CONDITIONS
Official Title
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singleton pregnancy less than 16 weeks gestation confirmed by ultrasound
- At least 1 high risk factor or 2 or more moderate risk factors for preeclampsia according to US Preventative Services Task Force (2021)
- Recommendation for 162mg aspirin daily during pregnancy
- Female aged 16 to 55 years old
You will not qualify if you...
- Contraindication to aspirin use
- Current or planned use of any other blood thinning medication
- Thrombocytopenia or other known platelet or bleeding disorders
- Abnormally high baseline PFA-100 epinephrine closure time before starting aspirin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19060
Actively Recruiting
Research Team
R
Rupsa C Boelig, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here